Get To Know Us

Charles McOsker, Ph.D.

Charles McOsker, Ph.D.

Co-founder & Chief Scientific Officer

Charles McOsker, Ph.D., is a veteran scientific executive with over 30 years of experience in drug discovery and development. Before joining Clarametyx, Dr. McOsker was Chief Technical Operations Officer at BioMotiv, which identifies and accelerates the development of breakthrough new therapeutics. Previously, Dr. McOsker founded Airway Therapeutics, which was created to develop pulmonary therapeutics based on the pulmonary research program at Cincinnati Children’s Hospital. Dr. McOsker has also served as Director of Business Development for the Drug Discovery Center at the University of Cincinnati. Dr. McOsker began his career at Procter & Gamble Pharmaceuticals, where he held both research and management positions in drug discovery and development over his 23-year tenure. Dr. McOsker received his bachelor’s degree in chemistry at Hope College in Michigan and his Ph.D. in biochemistry and molecular biology at Cornell University.

Close

Clarametyx Expanded Access Policy

Clarametyx Biosciences is a clinical stage biopharmaceutical company committed to developing novel immune-enabling therapies for serious or difficult-to-treat respiratory diseases.

“Expanded access” refers to use of an investigational drug outside of a clinical trial, where the use of the drug is for treatment, rather than gathering data in support of a marketing application.

The main goal of ongoing clinical trials for our investigational agent, CMTX-101, is to gain information about the drug’s safety and efficacy to submit an application to Health Authorities in support of approval to market CMTX-101. For this reason, Clarametyx believes that direct enrollment in a clinical trial is the preferred route of access to a drug, for which we are continuing to develop data on safety, efficacy and tolerability. We believe expanded access outside of a clinical trial may interfere with the conduct of ongoing trials and may disrupt the progress of our development programs, which could potentially delay access to other patients in need.

For this reason, Clarametyx is not making its investigational drugs available on an expanded access basis at the present time. We plan to re-evaluate this policy in the future as additional information becomes available from ongoing clinical trials.

If you have any questions about this policy or would like information about how to participate in our clinical studies, please contact us at info@clarametyx.com. More information on our ongoing clinical trial is available at ClinicalTrials.gov (http://www.clinicaltrials.gov, NCT06159725).

As authorized by the 21st Century Cures Act, Clarametyx may revise this expanded access policy at any time.